2012-11-30 10:46:32 -
Botanical and Plant-Derived Drugs: Global Markets - a new market research report on companiesandmarkets.com
- The global market for botanical and plant-derived drugs is expected to increase from $19.5 billion in 2008 to $32.9 billion in 2013, a compound annual growth rate (CAGR) of 11.0%.- Botanical drugs generated $127,000.0 in 2008. This segment should reach $2.4 billion in 2013 for a CAGR of 651.7%.- All other plant derived drugs generated $19.5 billion in 2008. This is expected to reach $30.5 billion in 2013, for a CAGR of 9.4%.
This study focuses on the global market for plant-derived drugs in light of the most recent available information. In addition to looking at future and current markets for a wide variety of new, reformulated, and established products, the study will analyze technological, environmental, legal/regulatory, and socioeconomic developments that may influence
the market for plant-derived drugs.This report provides an analysis of the emerging botanical drug industry and markets, geographically and by therapeutic area. The future of plant-derived drugs will also be discussed.More specific objectives are as follows:* Identify and classify the botanical and plant-derived drugs that have been commercialized to date
* Identify and evaluate the impact of factors that will drive future demand for botanical drugs with a focus too on plant-based drugs overall
* Forecast the volume and value of shipments of botanical drugs through 2013
* Describe botanical drugs that are currently in the clinical testing or approvals stage and assess the probability that they will be commercialized successfully in the next 5 years
* Forecast the potential market for these drug candidates, weighted to reflect the estimated probability that they will be commercialized
* Identify the leading manufacturers of plant-derived drugs and the firms that may become important players in the next 5 years
* Assess the long-term outlook for the plant-derived drugs industry, taking into account market opportunities as well as technological, environmental, legal/regulatory and socioeconomic factorsINTENDED AUDIENCEThe report has been written for the entire pharmaceutical community, but is tailored especially for readers with an interest in the marketing, management, and public policy dimensions of botanical drugs, including readers in the following:* The pharmaceuticals industry, especially companies supplying bulk or formulated plant-derived drugs, or companies that are planning to enter this field
* Medical research institutions
* International organizations and governmental organizations with relevant responsibilities such as health, drug safety, conservation and the environment, and foreign trade
* Investors
* The financial and analyst communitySCOPE OF REPORT
This report is an analytical business tool whose primary purpose is to describe the botanical drug industry with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward.
For the purposes of this report, botanicals are those drugs that are FDA approved under the botanical drug pathway, while plant-derived drugs are those under the FDA´s new classification, which includes both botanicals as well as other approved drugs that contain a mixture of natural plant-derived and synthetic substances.
The study´s main focus is on legal, prescription-required therapeutic medicines sold in the open market. The study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall "wellness" rather than to address a specific medical condition or symptoms). While there is a substantial market for these products, the medical value of many of these substances has not been demonstrated conclusively.
The study also does not cover the following:* Underground or illicit drugs
* Home remedies
* Tribal medicines
* Drugs derived from archaea, bacteria, and fungi (molds and yeasts)
* Non-medicinal plant substances such as laxative cellulose and pectin fiber
* Intravenously delivered nutrients of plant origin, such as dextrose
* Plant-derived substances serving as pharmaceutical excipients, such as starch, methylcellulose, guar gum, vegetable oils, fatty acids, cocoa butter, and candelilla wax
* Plant substances serving in cosmetics, toiletries, and personal care products
* Microbial fermentation products, even those made with culture media incorporating corn steep liquor, starch, or other plant-derived nutrients
* Marine lifeThe format of the study is organized around the following topics:* Major types and applications of botanical drugs with plant-derived drugs as their backdrop
* Industry structure
* Market size and segmentation, including breakdown of sales by therapeutic area and geographic area
* Market drivers
* Market projections through 2013
* Competition
* Observations and conclusions regarding the future of the botanical and plant-derived drug industry&
Click for report details:
www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports
www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports
www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports
www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.
